Loading the security page…
The series is stated in the current share scale after splits; dividends are not included in the price
Bio-Rad makes instruments for biological laboratories and clinical diagnostics.
The first half is equipment and consumables for research: instruments that separate proteins, count DNA molecules precisely and analyse cells. An instrument lasts years while reagents are bought continuously, which gives a steady half of revenue. Demand depends on the budgets of science and biotech companies.
The second is clinical diagnostics: kits for hospital laboratories, including quality control of other people's assays. A distinctive feature is a large stake in a European diagnostics maker: its revaluation moves reported profit more than the operating result does. Risks: research funding and demand in China. The company pays no dividend.
Based on the last 12 months of reports, through 30 June 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
The issuer has several share classes — market cap covers the whole company.
Share count is a period average, so market cap is approximate.
Bio-Rad Laboratories, Inc. (BIO) is a company in the Health care sector; its shares trade on NYSE.
The price of Bio-Rad Laboratories, Inc. (BIO) on October 30, 2026 is 370.36 $, −3.65 % on the day. Over 52 weeks the stock traded between 236.73 $ and 396.23 $; the price now sits 84 % of the way up that range. Over the past year the price changed by +19.28 %. The P/E ratio is 44.65, which is above the sector median (24.61). Market capitalization is 9.93 billion $, rank 8 among 23 stocks of the same industry with a known capitalization.
Bio-Rad Laboratories, Inc. trades on NYSE under the ticker BIO. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks BIO has traded between 236.73 $ and 396.23 $. As of 30 October 2026 the price stood 80.31 % of the way from the 52-week low to the high.
Over one year BIO shares rose 19.28 %; over six months they rose 25.33 %. Volatility over 90 days is 31.08 %. Dividends are not included: this is price change only, as of 30 October 2026.
BIO trades at a price-to-earnings ratio of 44.7, above the sector median of 24.6. Price to sales is 3.8, above the sector median of 3.6. Price to book is 1.4, below the sector median of 2.5. Calculated from reports for the period ending 30 June 2026.
Bio-Rad Laboratories, Inc. reported revenue of 2.6B $ and net income of 222M $ over the last four quarters. Net margin is 8.59 %. Revenue changed by +1.37 % year over year. Earnings per share are 8.21 $. Market capitalisation is 9.9B $.
BIO has a return on equity of 3.10 %, above the sector median of −40.58 %. Return on assets is 2.17 %, above the sector median of −30.08 %. Operating margin is 2.05 %, above the sector median of −20.96 %.